GlassScriptPhysician profile
Jonathan Finkelstein
NPI 1790930113
$11,417.57
in general payments reported to CMS, 2019-2025
35 companies · $3,255 in 2025
The $3,255 reported for 2025 was more than what 86% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,586 · 2020: $223 · 2021: $210 · 2022: $365 · 2023: $1,312 · 2024: $467 · 2025: $3,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554 · Travel and Lodging: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.95 |
| Travel and Lodging | $2,479.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,816.12 | 2019-2025 | General - Therapies, General - Pain Management, Intracept |
| Pacira Pharmaceuticals Incorporated | $568.79 | 2023 | Iovera, Zilretta, Exparel |
| Relievant Medsystems, INC. | $342.74 | 2022-2023 | Intracept |
| Biotronik Nro, INC. | $321.62 | 2025 | Prospera |
| Scilex Pharmaceuticals INC. | $274.19 | 2019-2024 | Ztlido |
| Medtronic USA, INC. | $261.79 | 2019-2020 | |
| Abbott Laboratories | $251.29 | 2019-2025 | Proclaim |
| Nevro Corp. | $234.15 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $180.58 | 2019-2024 | Xtampza, Belbuca |
| Stryker Corporation | $140.47 | 2019-2024 | Autoplex |
| Grt US Holding, INC. | $127.71 | 2022 | |
| Medtronic, INC. | $105.80 | 2022-2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $77.68 | 2019-2021 | |
| Protega Pharmaceutials INC | $70.85 | 2024-2025 | Roxybond |
| Valinor Pharma, LLC | $69.74 | 2023-2025 | Movantik |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $66.93 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $62.67 | 2024-2025 | |
| Depuy Synthes Sales INC. | $45.07 | 2019-2020 | |
| Elutia, INC. | $41.27 | 2019 | |
| Biodelivery Sciences International, INC. | $41.19 | 2020 | |
| Painteq LLC | $39.39 | 2024 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.64 | 2019-2023 | Relistor |
| Averitas Pharma INC. | $30.98 | 2023 | Qutenza |
| Forte Bio-Pharma LLC | $24.89 | 2023 | Prolate, Nalocet |
| Cumberland Pharmaceuticals, INC. | $23.24 | 2024 | Kristalose |
| Ultragenyx Pharmaceutical INC. | $22.28 | 2022 | |
| Kaleo, INC. | $20.05 | 2019 | |
| Ibsa Pharma INC. | $19.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.80 | 2019 | |
| Fidia Pharma USA INC. | $17.27 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.94 | 2019 | |
| Pfizer INC. | $14.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2022 | |
| Saluda Medical Americas, INC. | $13.49 | 2025 | Evoke |
| Allergan, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Finkelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.